Actively Recruiting
Cardiometabolic evalUation REgistry of Heart Failure
Led by Ruijin Hospital · Updated on 2025-04-23
5000
Participants Needed
1
Research Sites
804 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a combined retrospective-prospective observational cohort study investigating the role of systemic and local cardiometabolic risk factors in cardiac structural/functional remodeling and clinical outcomes among heart failure (HF) patients. The study integrates retrospective clinical data (from the past 10 years) and prospective longitudinal follow-up (5 years) of HF patients across HF with reduced (HFrEF), mildly-reduced (HFmrEF), preserved (HFpEF) and improved ejection fraction (HFimpEF) phenotypes. Systemic metabolic factors (e.g., blood lipid profiles, glycemic levels, insulin resistance) and local factors (e.g., epicardial adipose tissue \[EAT\], perivascular adipose tissue \[PVAT\]) will be analyzed for their associations with changes in cardiac geometrics and function, dynamic transitions between HF phenotypes, as well as the occurrence of major adverse cardiovascular events (MACEs). The study seeks to advance risk stratification by integrated evaluation of cardiometabolic profiles so as to refine personalized cures in HF management.
CONDITIONS
Official Title
Cardiometabolic evalUation REgistry of Heart Failure
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Chronic heart failure (NYHA class II to IV) including:
- HFrEF: symptoms or signs of HF and left ventricular ejection fraction (LVEF) 40% or less
- HFimpEF: symptoms or signs of HF with previous LVEF 40% or less and follow-up LVEF above 40%
- HFmrEF: symptoms or signs of HF and LVEF between 41% and 49%
- HFpEF: symptoms or signs of HF, LVEF 50% or more, and evidence of cardiac structural or functional abnormalities such as diastolic dysfunction or raised filling pressures with raised natriuretic peptide
You will not qualify if you...
- Estimated survival of 1 year or less
- Pregnant, breastfeeding, or planning to give birth within one year
- Poor compliance or unable to follow up
- Mental or physical condition preventing written informed consent
- Unwillingness to give informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, China, 200025
Actively Recruiting
Research Team
C
Chendie Yang, M.D., Ph.D.
CONTACT
X
Xiaoqun Wang, M.D., Ph.D.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here